Department of Health and Human Services
Public Health Service
5100 Paint Branch Pkwy, HFS-607
November 9, 2005
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED
CHS International Research, Ltd.
927 N Main St
Orange, CA 92867
Dear Sir or Madam:
This is to advise you that the Food and Drug Administration (FDA) has reviewed your website at the Internet address www.chsir.com and has determined that the product Growyoung™ Soy Isoflavones with Genistein and Daidzein 150mg is promoted for conditions that cause the product to be a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)(B)]. The therapeutic claims on your website establish that the product is a drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease. The marketing of this product with these claims violates the Act.
Examples of some of the claims observed on your website include:
- "Isoflavones help to reduce the chance of developing hormone-related cancers"
- "Isoflavones' anti-oxidant properties help to reduce the cancer risks."
- "Isoflavones help to prevent the angiogenic process during the cancer development."
- "Isoflavones help to arrest the spread of cancer by blocking an enzyme called tyrosine protein kinase, which cancerous cells used during their accelerated growth."
- "Estrogen and xenoestrogens increase the breast risk by binding with estrogen receptors and triggering the release of the tumor growth factor, the phytoestrogen [sic] reduce breast cancer by usurping the xenoestrogen.…"
- "Soy Isoflavones also reduce the risk of cancer of endomerium [sic] and other type of cancers. It reduced the colon cancer risk by 40%; it reduced the risk of lung cancer and prostate cancer, stomach cancer."
- "The benefit of prevention of osteoporosis."
- "Ipriflavones — a substance similar to the isoflavones has been shown … to be … promising as an alternative treatment for osteoporosis."
Furthermore, your product is not generally recognized as safe and effective for the above referenced conditions and therefore, the product is also a "new drug" under section 201(p) of the Act [21 USC 321(p)]. New drugs may not be legally marketed in the US without prior approval from FDA as described in section 505(a) of the Act [21 USC 355(a)]. FDA approves a new drug on the basis of scientific data submitted by a drug sponsor to demonstrate that the drug is safe and effective. Your Growyoung™ Soy Isoflavones with Genistein and Daidzein 150mg is also misbranded within the meaning of section 502(f)(1) of the Act, in that the labeling for this drug fails to bear adequate directions for use [21 USC 352(f)(1)].
This letter is not an all-inclusive review of your website and the products that your firm markets. It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations. The Act authorizes injunctions against manufacturers and distributors of illegal products and seizure of such products [21 USC 332 and 334]. You should take prompt action to correct the violations identified in this letter and any other violations of the Act. Failure to do so may result in enforcement action without further notice.
Furthermore, you should be aware that laws enforced by the Federal Trade Commission (FTC) govern claims made in advertising, including print, broadcast, websites, and other electronic media. The FTC Act, 15 USC 41 et seq., prohibits unfair or deceptive acts and practices, including false and unsubstantiated advertising claims. It is against the law to make health claims without substantiation or to overstate the health benefits of the products you promote. Be aware that product claims can be communicated to consumers in a variety of ways, including product name, website name, product testimonials, endorsements, or use of metatags.
Please advise this office, in writing, within fifteen (15) working days of the receipt of this letter, as to the specific steps you have taken to correct the violations noted above and to assure that similar violations do not occur. If corrective actions cannot be completed within fifteen working days, state the reason for the delay and the time within which the corrections will be completed.
Your reply should be addressed to Quyen Tien, Compliance Officer, at the above letterhead address.
Joseph R. Baca
This page was posted on March 28, 2006.